Authors


Owen Corbin

Latest:

Confidentiality in DCT: How to Utilize Third-Party Home Health Providers

Alleviating sponsor and investigator concerns around sharing of remote-assessment data in accordance with GCP and GDPR standards.


Jonathan Jackson

Latest:

Importance of Diversity in Parkinson’s Research

Eliminating barriers to engage underrepresented populations.


C.K. Wang, MD

Latest:

Real-World Data Offers Significant Opportunities for Developing New Therapies for Hematologic Cancers

By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.


Roger Sands

Latest:

WiFi Automation Keeps Decentralized Clinical Trials Running

Reliable internet connection an integral part of movement to DCTs.


WCG Clinical

Latest:

WCG Randomized 1,600 Participants for RSV Vaccine Trial

A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.


Jian Wang, PhD

Latest:

Integration of Point-of-Care Devices in Clinical Trials

A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.


Christine Senn

Latest:

From Isolation to Integration: Improving Site-Sponsor Collaboration in Clinical Trial Startup

It takes a village to raise a trial, but most stakeholders are siloed on isolated islands.


Megan Hooton

Latest:

Building Relationships Key for Smaller Sponsors

Strong collaboration critical as trial development advances.



Vivek Vaishya

Latest:

Future of Clinical Trial Documentation Management: eTMF Integrated with Blockchain

eTMF-blockchain technology offers a myriad of application benefits to data quality and integrity while ensuring compliance to ethical standards.


Teonna Woolford

Latest:

Making Clinical Research More Equitable Makes for More Effective Medications

Decentralized trials provide promise for lowering barriers in participation, but industry must continue to be proactive in patient centricity.


Nick Collins

Latest:

eSource Interoperability Between EHR and EDC

Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.


Jade Dennis

Latest:

Towards Data-Driven Clinical Trial Planning and Strategy

Optimizing feasibility through increased data collection.


Karoline Hahn

Latest:

Somatic Cell Therapy—Navigating the Regulatory Landscape

The diversified sources of the somatic cells call for additional oversight to prevent the introduction, transmission, and spread of communicable disease.


Gabi Hanna, MD

Latest:

Moving Toward the Pharmaceutical Industry of the Future with Translational Medicine

Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.


Michael Wilkinson

Latest:

Enabling Digital Transformation: Managing External Clinical Data Sources to Advance Drug Development

With an increasing amount of diverse data that must now be collected and analyzed, the industry is faced with increasingly complex studies that present new challenges in data management.


Aaron Mann

Latest:

Establishing a Basis for Secondary Use Standards for Clinical Trials

Study seeks to understand how different forms of data meet the needs of researchers.


Avacare

Latest:

Clinical Trial Diversity in Action: A Site Roadmap for Sponsors and CROs

Webinar Date/Time: Wed, Oct 30, 2024 11:00 AM EDT


Tom Zietlow, PhD

Latest:

C-Suite Survey Underscores Digital Technology’s Growing Role in Clinical Trials

Findings from the most recent Biopharma Confidence Index show that the pandemic has substantially influenced biopharma executives’ expectations in key areas like artificial intelligence/machine learning and real-world evidence.


Michael DePalma

Latest:

How NLP, OCR, and Social Graphs Accelerate Subject Recruitment for Clinical Trials

Explore how natural language processing and social graph techniques help to tackle the challenge of patient and investigator recruitment and raise the success rate of clinical trials.


Sam Whitaker and Jason Dong

Latest:

Increasing Clinical Trial Diversity Through Patient-First Payment Options

Patient-first trial design, based around the tenets of adaptability and personalization, has emerged as a key solution to increase diversity and improve trial outcomes for all.


Rakshinda Mujeeb, PharmD

Latest:

Clinical Trial Feasibility Observations

Changing the expectations of the feasibility study can improve the process.


Michael Agard

Latest:

Enhancing Trial Master File Quality With Pareto Charts and Funnel Charts

Hidden costs have industry searching for ways to not only identify quality issues, but completely eliminate them from the start.


Sowmyanarayan Srinivasan, Priyanshi Gautam, and Garima Prashad

Latest:

Re-imagining the Labs

Developing a strategic approach for labs that can identify and tackle global health challenges.


Ashley Moultrie, CCRP

Latest:

The Consequences of Underrepresentation in Clinical Trial Design

A representative sample patient population that accurately reflects the overall population is vital to establish the safety and efficacy of a drug.


Neta Bendelac

Latest:

Introducing Sustainability into the Clinical Trial Supply Chain

Identifying areas of burden and steps supply chain operators can take to alleviate them.


Oleksii Korzh, MD, PhD

Latest:

Clinical Trials in Ukraine During the War

Industry must take steps in preserving data for use after the war.


Charles T. Lancaster

Latest:

De-Risking Trials with Science-Driven Oversight

Identifying the ‘significant six’ areas of clinical study conduct to mitigate risk.


Andreas Dreps

Latest:

Overcoming Challenges in the Development of Antibody Drug Conjugates

For antibody drug conjugates to reach their full potential, developers should focus on addressing current challenges such as safety and efficacy.


Cindy Henderson

Latest:

Accelerating Clinical Trial Design and Operations

Fully-integrated, component-based CDMS offers flexibility, customization, and efficiency.

© 2024 MJH Life Sciences

All rights reserved.